Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) EBIT: 2023-2025

Historic EBIT for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$60.1 million.

  • Immunome's EBIT fell 19.03% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 26.23%. This contributed to the annual value of -$305.8 million for FY2024, which is 179.19% down from last year.
  • Latest data reveals that Immunome reported EBIT of -$60.1 million as of Q3 2025, which was down 29.39% from -$46.5 million recorded in Q2 2025.
  • Immunome's EBIT's 5-year high stood at -$4.5 million during Q1 2023, with a 5-year trough of -$132.3 million in Q1 2024.
  • Its 3-year average for EBIT is -$51.5 million, with a median of -$46.5 million in 2025.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 2,859.05% in 2024, then skyrocketed by 66.26% in 2025.
  • Immunome's EBIT (Quarterly) stood at -$94.7 million in 2023, then increased by 12.34% to -$83.0 million in 2024, then declined by 19.03% to -$60.1 million in 2025.
  • Its EBIT was -$60.1 million in Q3 2025, compared to -$46.5 million in Q2 2025 and -$44.6 million in Q1 2025.